臨床検査57巻12号

2013年11月発行

今月の特集1 前立腺癌マーカー

前立腺癌の診断，治療，フォロー　

著者： 小坂威雄¹ 大家基嗣¹

所属機関： ¹慶應義塾大学医学部泌尿器科学教室

ページ範囲：P.1438 - P.1447

■前立腺癌は，今後，男性癌の癌罹患率第1位となることが推定されている．

■直腸診や，血液検査による前立腺特異抗原（PSA）測定にて前立腺針生検の適応が考慮され，病理組織診断にて確定診断される．

■PSA，Gleason score（GS），画像診断による病期診断の3つを組み合わせたリスク分類に基づき，治療方針の適応が検討される．

■手術療法・放射線療法・ホルモン療法，それぞれの長所と短所，ならびに患者の価値観を考慮したうえで治療方針が決定される．

参考文献

1）Suzuki T, Matsuo K, Wakai K, et al：Effect of familial history and smoking on common cancer risks in Japan. Cancer　109：2116-2123，2007

2）Pedersen KV, Carlsson P, Varenhorst E, et al：Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ　300：1041-1044，1990

3）Gosselaar C, Roobol MJ, Roemeling S, et al：The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol　54：581-588，2008

4）Hugosson J, Carlsson S, Aus G, et al：Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol　11：725-732，2010

5）Schröder FH, Hugosson J, Roobol MJ, et al：Screening and prostate-cancer mortality in a randomized European study. N Engl J Med　360：1320-1328，2009

6）Cancer Registration Committee of the Japanese Urological Association: Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol　12：46-61，2005

7）Thompson IM, Pauler DK, Goodman PJ, et al：Prevalence of prostate cancer among men with a prostate-specific antigen level ＜ or =4.0 ng per milliliter. N Engl J Med　350：2239-2246，2004

8）Vickers AJ, Wolters T, Savage CJ, et al：Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol　56：753-760，2009

9）Gretzer MB, Partin AW：PSA markers in prostate cancer detection. Urol Clin North Am　30：677-686，2003

10）Punglia RS, D’Amico AV, Catalona WJ, et al：Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med　349：335-342，2003

11）Ito K, Yamamoto T, Kubota Y, et al：Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology　56：278-282，2000

12）Guess HA, Gormley GJ, Stoner E, et al：The effect of finasteride on prostate specific antigen: review of available data. J Urol　155：3-9，1996

13）Marks LS, Andriole GL, Fitzpatrick JM, et al：The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol　176：868-874，2006

14）Kikuchi E, Nakashima J, Ishibashi M, et al：Prostate specific antigen adjusted for transition zone volume : the most powerful method for detecting prostate carcinoma. Cancer　89：842-849，2000

15）Eichler K, Hempel S, Wilby J, et al：Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol　175：1605-1612，2006

16）Hara R, Jo Y, Fujii T, et al：Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology　71：191-195，2008

17）Takenaka A, Hara R, Hyodo Y, et al：Transperineal extended biopsy improves the clinically significant prostate cancer detection rate: a comparative study of 6 and 12 biopsy cores. Int J Urol　13：10-14，2006

18）Kawakami S, Yamamoto S, Numao N, et al：Direct comparison between transrectal and transperineal extended prostate biopsy for the detection of cancer. Int J Urol　14：719-724，2007

19）Djavan B, Ravery V, Zlotta A, et al：Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4 : when should we stop? J Urol　166：1679-1683，2001

20）Keetch DW, Catalona WJ, Smith DS：Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol　151：1571-1574，1994

21）Helpap B, Egevad L：Modified Gleason grading. An updated review. Histol Histopathol　24：661-666，2009

22）Epstein JI, Allsbrook WC Jr, Amin MB, et al：Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol　13：57-59，2006

23）Seitz M, Shukla-Dave A, Bjartell A, et al：Functional magnetic resonance imaging in prostate cancer. Eur Urol　55：801-814，2009

24）Hövels AM, Heesakkers RA, Adang EM, et al：The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol　63：387-395，2008

25）Briganti A, Passoni N, Ferrari M, et al：When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol　57：551-558，2010

26）D’Amico AV, Whittington R, Malkowicz SB, et al：Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA　280：969-974，1998

27）National Comprehensive Cancer Network：NCCN clinical guidelines in oncology Prostate Cancer version 2. 2013, NCCN, Washington，2013

28）Walsh PC, Donker PJ：Impotence following radical prostatectomy: insight into etiology and prevention. J Urol　128：492-497，1982

29）Eggleston JC, Walsh PC：Radical prostatectomy with preservation of sexual function : pathological findings in the first 100 cases. J Urol　134：1146-1148，1985

30）Schumacher MC, Burkhard FC, Thalmann GN, et al：Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol　54：344-352，2008

31）Wilson LC, Gilling PJ：Post-prostatectomy urinary incontinence: a review of surgical treatment options. BJU Int　107（Suppl 3）：7-10，2011

32）Namiki S, Ishidoya S, Ito A, et al：Quality of life after radical prostatectomy in Japanese men : a 5-Year follow up study. Int J Urol　16：75-81，2009

33）Savera AT, Kaul S, Badani K, et al：Robotic radical prostatectomy with the “Veil of Aphrodite” technique: histologic evidence of enhanced nerve sparing. Eur Urol　49：1065-1073，2006；discussion 1073-1074

34）Alicikus ZA, Yamada Y, Zhang Z, et al：Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer　117：1429-1437，2011

35）Kuban DA, Levy LB, Cheung MR, et al：Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys　79：1310-1317，2011

36）Intensity Modulated Radiation Therapy Collaborative Working Group: Intensity-modulated radiotherapy : current status and issues of interest. Int J Radiat Oncol Biol Phys　51：880-914，2001

37）Nihei K, Ogino T, Onozawa M, et al：Multi-institutional Phase Ⅱ study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int J Radiat Oncol Biol Phys　81：390-396，2011

38）Ishikawa H, Tsuji H, Kamada T, et al：Carbon ion radiation therapy for prostate cancer: results of a prospective phase Ⅱ study. Radiother Oncol　81：57-64，2006

39）Zelefsky MJ, Yamada Y, Pei X, et al：Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology　77：986-990，2011

40）Nag S, Beyer D, Friedland J, et al：American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys　44：789-799，1999

41）Deger S, Boehmer D, Türk I, et al：High dose rate brachytherapy of localized prostate cancer. Eur Urol　41：420-426，2002

42）Nieder AM, Porter MP, Soloway MS：Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol　180：2005-2009，2008

43）Huggins C, Hodges CV：Studies on prostatic cancer. Ⅰ. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin　22：232-240，1972

44）Labrie F, Dupont A, Belanger A, et al：Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem　23：833-841，1985

45）Scher HI, Fizazi K, Saad F, et al：Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med　367：1187-1197，2012

46）Tran C, Ouk S, Clegg NJ, et al：Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science　324：787-790，2009

47）Fizazi K, Scher HI, Molina A, et al：Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol　13：983-992，2012

48）Ryan CJ, Smith MR, de Bono JS, et al：Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med　368：138-148，2013

49）Hara T, Kouno J, Kaku T, et al：Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. J Steroid Biochem Mol Biol　134：80-91，2013

50）Roach M 3rd, Hanks G, Thames H Jr, et al：Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys　65：965-974，2006

51）Scher HI, Halabi S, Tannock I, et al：Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol　26：1148-1159，2008